Tropos’ ALS therapy included on Windhover’s Top 10 Neuroscience Projects to Watch

Elsevier Business Intelligence/Windhover Conferences last week released their list “Top 10 Projects to Watch” in anticipation of the November Therapeutic Area Partnerships meeting. The list offers a powerful Top 10 endorsement in the cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune categories. In the neuroscience arena, Trophos was selected for its TRO19622 therapy for the treatment of ALS. EnVivo Pharmaceuticals Inc.(a competitor in Prize4Life’s ALS Treatment Prize), Prana Biotechnology, and Allon Therapeutics were also listed among the top 10 for therapeutics currently being developed for neurodegenerative diseases and which may be applicable for the treatment of ALS as well. NeurAxon Inc., Alexza, AFRAXIS, Karo Bio, CeNeRx, and Braincells rounded out the list. The Therapeutic Area Partnerships event is a highly targeted meeting for life science companies, often resulting in strategic and profitable alliances; past Windhover top 10 candidates signed a total potential value of $17 billion US in acquisitions and alliances following their listing. See the entire “Top Projects to Watch” list here.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail